KROS
Keros Therapeutics Inc
11.60$
-0.7%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 6,887.5% | 172.7% | 333.7% | 827.0% | 80.9% | 10.9% | 0.2% | 2.0% | 2.8% | 103.9% | 109.8% | – | – | |
| -6,787.5% | 100.0% | 100.0% | 100.0% | 19.1% | 89.1% | 100.0% | 98.0% | 97.2% | 100.0% | -9.8% | – | – | |
| 426,750.0% | 26,218.9% | 46,094.0% | 109,500.0% | 12,686.9% | 1,500.0% | 23.1% | 239.4% | 136.9% | 4,652.5% | 4,386.1% | 122.9% | 228.6% | |
| 114,350.0% | 6,367.1% | 12,419.3% | 26,921.6% | 2,530.9% | 350.6% | 5.0% | 79.7% | 71.0% | 3,050.1% | 2,764.9% | 47.4% | 122.4% | |
| 534,212.5% | 32,586.0% | 58,513.3% | 136,421.6% | 15,136.9% | 1,839.7% | 28.0% | 317.1% | 205.1% | 7,702.6% | 7,041.1% | 170.3% | 348.6% | |
| -541,000.0% | -32,486.0% | -58,413.3% | -136,321.6% | -15,117.8% | -1,750.6% | 72.0% | -219.2% | -107.9% | -7,602.6% | -7,051.0% | -170.3% | -305.8% | |
| 0.0% | 0.0% | – | – | – | – | – | – | – | – | – | – | – | |
| -493,000.0% | -28,142.0% | -51,944.6% | -122,316.2% | -13,648.5% | -1,503.2% | 75.0% | -181.2% | -61.0% | -6,487.0% | -6,459.9% | -158.0% | -259.5% | |
| -2,625.0% | 2,665.7% | -333.7% | – | – | 9.9% | 4.8% | -12.2% | -10.0% | -393.2% | – | 12.2% | – | |
| -493,000.0% | -28,142.0% | -51,944.6% | -122,316.2% | -13,648.5% | -1,513.0% | 70.3% | -169.0% | -51.0% | -6,093.8% | -6,459.9% | -158.0% | -250.6% | |
| -486,112.5% | -27,969.2% | -51,610.8% | -121,489.2% | -13,567.5% | -958.0% | 75.2% | -179.2% | -58.3% | -6,383.1% | -6,350.1% | -155.8% | -254.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.